Akari Therapeutics AKTX Stock
Akari Therapeutics Price Chart
Akari Therapeutics AKTX Financial and Trading Overview
| Akari Therapeutics stock price | 1.19 USD |
| Previous Close | 0.16 USD |
| Open | 0.17 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 0.16 - 0.17 USD |
| 52 Week Range | 0.14 - 1.61 USD |
| Volume | 91.51K USD |
| Avg. Volume | 565.21K USD |
| Market Cap | 16.08M USD |
| Beta (5Y Monthly) | 1.309289 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.58 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.75 USD |
AKTX Valuation Measures
| Enterprise Value | 2.52M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.9352941 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 6.6249995 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.109 |
Trading Information
Akari Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.309289 |
| 52-Week Change | -84.25% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.61 USD |
| 52 Week Low | 0.14 USD |
| 50-Day Moving Average | 0.18 USD |
| 200-Day Moving Average | 0.43 USD |
AKTX Share Statistics
| Avg. Volume (3 month) | 565.21K USD |
| Avg. Daily Volume (10-Days) | 401.05K USD |
| Shares Outstanding | 101.12M |
| Float | 55.88M |
| Short Ratio | 0.44 |
| % Held by Insiders | 16.12% |
| % Held by Institutions | 8.92% |
| Shares Short | 216.65K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -113.26% |
| Return on Equity (ttm) | -483.24% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -23084500 USD |
| Net Income Avi to Common (ttm) | -17748062 USD |
| Diluted EPS (ttm) | -0.28 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 13.25M USD |
| Total Cash Per Share (mrq) | 0.13 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.147 |
| Book Value Per Share (mrq) | 0.024 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -21504522 USD |
| Levered Free Cash Flow (ttm) | -6044853 USD |
Profile of Akari Therapeutics
| Country | United States |
| State | N/A |
| City | London |
| Address | 75/76 Wimpole Street |
| ZIP | W1G 9RT |
| Phone | 44 20 8004 0270 |
| Website | https://www.akaritx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
Q&A For Akari Therapeutics Stock
What is a current AKTX stock price?
Akari Therapeutics AKTX stock price today per share is 1.19 USD.
How to purchase Akari Therapeutics stock?
You can buy AKTX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Akari Therapeutics?
The stock symbol or ticker of Akari Therapeutics is AKTX.
Which industry does the Akari Therapeutics company belong to?
The Akari Therapeutics industry is Biotechnology.
How many shares does Akari Therapeutics have in circulation?
The max supply of Akari Therapeutics shares is 26.47M.
What is Akari Therapeutics Price to Earnings Ratio (PE Ratio)?
Akari Therapeutics PE Ratio is now.
What was Akari Therapeutics earnings per share over the trailing 12 months (TTM)?
Akari Therapeutics EPS is -2.58 USD over the trailing 12 months.
Which sector does the Akari Therapeutics company belong to?
The Akari Therapeutics sector is Healthcare.
Akari Therapeutics AKTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| NASDAQ Capital Market Composite RCMP | 96.46 USD — |
-4.76
|
— — | 95.94 USD — | 97.68 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 20257.83 USD — |
-5.96
|
— — | 20236.33 USD — | 20672.41 USD — | — - | — — |
- {{ link.label }} {{link}}